Contact Us
Home Page

May 2018


Feb 2016

Xanthochromia - A QC to aid in the monitoring of Subarachnoid Haemmorrhage

Cambridge Life Sciences in conjunction with ADP is now able to offer Xanthochromia - a Cerebral Spinal Fluid (CSF) QC, intended for use as a quality control to monitor the performance of laboratory screening of CSF for the presence of haemoglobin and/or bilirubin.

Available as a frozen liquid stable format, single or bi-level, 1.0 or 0.5ml vials.

Typical values Level 1, NOA 0.100 ......NBA 0.008,   Level 2 NOA 0.160.......NBA 0.045

Please contact us if you would like further information.


Dec 2015

New CLS Paracetamol Sera Calibrators for improved accuracy and sensitivity

As proof that CLS really does listen to its customers and following customer feedback and evaluation, Cambridge Life Sciences is now pleased to be able to offer new Paracetamol Sera Calibrators to go alongside the popular K8002 and K8003 Paracetamol Kits.  The key features include:- 

• Human sera based calibrators to improve accuracy and sensitivity

• Sensitivity: <3mg/L (0.02mmol/L)

• Measurement range: 3 - 378mg/L (0.02 - 2.50mmol/L)

• Calibration frequency: 168 hours

• Liquid ready to use 

Each Paracetamol Sera Calibrator Kit contains 4 x 0 mmol/L (0 mg/L) and 4 x 2mmol/L (302 mg/L) in 0.5ml vials.  Please find attached a datasheet which features more information on sensitivity, precision, linearity and calibration stability. All the other claims for both products remain unchanged. 

Protocols are available for most clinical chemistry automates. A datasheet is available here

Please contact us if you would like further information or an IFU specific to your analyser.


Oct 2015


Sep 2015

Dr Suzanne Turner in the Department of Pathology is the coordinator of a successful bid for a €4 million European Union Marie Curie Innovative Training Network

This ETN is embedded into an established international research programme; The European Research Initiative on Anaplastic Lymphoma Kinase (ALK)-related malignancies (ERIA; is an existing and functional network of 13 partners, which will cosset and nurture a cohort of early stage researchers to become confident, competent, independent and well-connected European scientists with excellent career perspectives. ERIA was instigated to coordinate research into ALK-related malignancies to facilitate the development of less-toxic and more efficacious therapies. ALK is increasingly recognised as a prevalent oncogene in a number of human malignancies and therefore poses a prominent clinical problem, which requires coordinated research into its oncogenic mechanisms. ERIA now conducts a collaborative multidisciplinary research programme at the interface of biomedical and bio-mechanistic approaches, which will be an excellent environment to train the next generation of European scientists. The 15 recruited fellows will be incorporated into international academic study groups (all partners of the ERIA network) to perform high calibre research and also will be exposed to environments from other sectors to broaden their experience. Secondments will include technical training within individual laboratories and SMEs (TissueGnostics, Galkem, Cambridge Life Sciences, Sofigen and Varionostics) as well as large Pharma (Roche). Training through research will be complemented with a balanced programme of transferable skills and access to local courses. The training of each fellow will be guided by a personal career development plan and supervised by a PhD committee panel. The primary goal of the network is to train the recruited fellows by participation in an internationally competitive research programme and integrating them into an international network. Thereby providing competence in state-of-the-art research and development at the forefront of translational science.

With a score of 95.4 the ETN made it into the top 6.3 % out of more than 1,300 proposals to obtain an invitation for funding. This makes European Training Networks one of the most competitive funding opportunities available within HORIZON2020. “With ERIA we have based this proposal on an existing network of academic research collaboration, which will now be reinforced through the incorporation of several companies. I hope this will speed up the translation of our research into novel and improved therapies” said Dr Suzanne Turner. The core focus of the consortium which is called ALKATRAS: Break free from cancer, is to investigate mechanisms employed by the ALK oncogene to induce a variety of cancers including lymphoma, neuroblastoma and lung cancer. In doing so, it is hoped that novel therapeutic targets will be discovered and treatments for these developed together with the assistance of a number of companies based within Europe.



Mar 2015

BlueDiver range of products from D-Tek

The BlueDiver Instrument is a compact and innovative machine which processes the strips with ready-to-use reagents provided in individual cartridges.

This “no pump – no liquid handling” machine presents many advantages such as a time-effectiveness (results are obtained in only 1 hour), limited maintenance (no pumps/tubes to be serviced or replaced), space-effectiveness (BlueDiver Instrument is as compact as a microwave oven)

Moreover the specific architecture of the BlueDiver Instrument and the standardised test procedures allow the testing of 24 different samples on 24 similar or completely different test strips. This fact combined with the tremendous reduction of processing time gives maximum flexibility to laboratory technicians.

The BlueDiver Instrument has been conceived to comply with the CE IVD recommendations and major laboratory accreditation requirements.

  • Space saving - As compact as a microwave oven
  • No risk of contamination - No pumps, no liquid handling, no dead volume, works with ready to use and disposable reagents cartridges
  • Flexible - From 1 to 24 similar or different assays can be run simultaneously
  • Easy to use - Simply load the Immunodot Strips, the reagent cartridges, the patient
    samples, press on and follow the test processing data through a user friendly touch screen
  • Automatic check-in - Through a barcode association between the strips and the reagent cartridges
  • Unequalled short testing time - Thanks to an Innovative processing principle
  • Open system - Compatible with the whole range of D-Tek’s Immunodot products and with a large panel of other Immunoassays

A video of the BlueDiver instrument in action can be found here here


BlueDiver Dot kits are composed of 24 nitrocellulose strips on which the antigens have been coated in a dot-shaped format. One strip allows the testing of one patient for many different autoantibodies in the same run. The test is based on a classical Enzyme ImmunoAssays (EIA).

In addition to the antigens, each strip possesses two built-in reactive controls :

  • The first one, the Reaction Control (RC), controls the validity of the test : its coloration proves that the clinician has added the patient serum and that the test has functioned correctly.
  • The second one, the Cut-Off Control (CO), allows the interpretation of the test : any color intensity equal to or below that of the cut-off is considered negative, any color intensity superior to that of the cut-off is considered positive.


The BlueDiver Dot are automated on the BlueDiver Instrument. The complete processing time lasts just 1 hour. The results can be interpretated by sight or a semi-quantification can be obtained thanks to the BlueScan scanner and the Dr DOT software (minimum version 3).

Key characteristics

  • Indication : Suitable for small to high throughput laboratories or hospitals
  • Support of reaction : nitrocellulose (strip)
  • Volume of sample needed : 10 µl
  • Number of autoantibodies detected : up to 12
  • Test duration : 1h
  • Testing : BlueDiver Instrument
  • Reading : Visual or BlueScan + Dr DOT software (minimum version 3)
  • Results : Qualitative or semi-quantitative
  • Controls : Positive and negative built-in controls

For more information on the range of kits available, please contact us



Feb 2015

Eurolyser range of products

Cambridge Life Sciences now offers new Near Patient Diagnostics (NPD) products with the introduction of the Eurolyser range. enabling true clinical diagnostics to be performed quickly and simply at primary care level or in the community.

• Technology is simple to operate and can be performed by Nurse or HCA. Built in interpretation algorithm based on current clinical guidelines.

• Unlike some POC (Point of care tests) already in use the results are quantitative not
qualitative so provide more relevant clinical information.

• Small foot print devices require no permanent installation or specialist operating

• Fully supported by UK based teams All instruments and reagents compliant with IVD directive and are CE marked.

• Patients can receive results during single visit to Practice. Max test time is 20 minutes from blood taken to result available.

• Faster diagnosis ensures treatment plan in place faster, potentially reducing treatment cost and recovery times.

• Can help with admission avoidance to Secondary care, especially in some acute cases
such as chest pain or DVT.

Single instrument for multiple tests simplifies user training, reduces running costs and
capital costs. For example our SMART device can perform INR, HBa1C, CRP, Troponin, CysC, 
D.Dimer, FOB, Micro Albumin, and Ferratin

                    CUBE instrument                                   SMART instrument

For further information please contact us


November 2013


July 2013

Introducing the Diazyme 25-Hydroxy Vitamin D Enzyme Immunoassay


In line with current clinical needs, Diazyme’s new 25-Hydroxy Vitamin D Assay measures total true 25-Hydroxy Vitamin D levels (D2 + D3 levels) in both serum and plasma samples. Furthermore, the assay fully automates the removal of non-specific protein binding and cross reactivity that may occur in competing assays, thereby assuring results will be both precise and accurate.  The 25-Hydroxy Vitamin D assay is both fast and flexible with complete testing results in under 2 hours, making it one of the fastest and most efficient in the marketplace.  The test is user-friendly and can be used manually or easily adapted for use on a wide range of fully automated microtiter plate readers, making it suitable for use in laboratories of all sizes and testing needs.

Traditionally, testing of Vitamin D levels has been predominantly used for the diagnosis and management of patients with Vitamin D deficiency. Recent clinical studies though have linked Vitamin D deficiency to various diseases including cancers, cardiovascular disease, diabetes, osteoporosis, multiple sclerosis, Alzheimer’s disease and all-cause mortality.  This new understanding of importance of Vitamin D levels has driven an increase in the number of physician requests for total 25-Hydroxy Vitamin D tests. “Diazyme’s new 25-Hydroxy Vitamin D assay provides a convenient and cost effective test method for laboratories of virtually all sizes” said Dr. Chong Yuan, Managing Director of Diazyme Laboratories. “The assay measures the total Vitamin D, and the results are traceable to the National Institute of Standards and Technology (NIST) standard for vitamin D.  The assay takes a much shorter time and can be fully automated when it is run on ELISA instruments such as the Dynex DS2® and DSX® platforms. This unique set of features makes the Diazyme 25-Hydroxy Vitamin D assay a valuable diagnostic test for assessing this important analyte.”  

The new competitively priced Vitamin D kit (DZ6888B-K) is available to buy now from Cambridge Life Sciences. Please contact us for further information.




May 2013



I am pleased to announce that Cambridge Life Sciences Limited (CLS) has acquired Hillside Medical Supplies Ltd. (Hillside Medical).

Hillside Medical is a medical supplies company specialising in the sale of a wide variety of medical supplies and diagnostic devices to the UK Primary Care community. Hillside has had a long and successful relationship with companies such as Welch Allyn, Clement Clarke, Vitalograph, Heine, Seca, Huntleigh, Lec, Shoreline, Labcold, Sidhil, Sunflower, Plinth, Eschmann, Daray, Luxo and many more providing cost effective solutions to Primary Care throughout the UK.

Cambridge Life Sciences is an in vitro diagnostic company that develops, manufactures and distributes its products worldwide in over 20 countries. Together with some of its distribution partners CLS has developed a marketing strategy to take in vitro diagnostic tests closer to the patient. This near patient strategy necessarily includes the Primary Care community in the UK.

The acquisition of Hillside Medical provides a vehicle for CLS to access this developing near patient testing market, as well as allowing some of the more specialist devices available to Hillside Medical to be sold into the UK hospital market in support of the CLS product range.

Hillside Medical Supplies will continue to operate as a separate company taking advantage of the skills and abilities of the staff that have been responsible for growing the business to date.

The concentration on customer service and the ability to tailor solutions to specific customer needs will remain at the heart of both businesses, and we look forward to our customers benefiting from the continuity and synergies that this partnership will bring.

Peter Blake

Chief Executive

click here for full press release



May, 2012

A.Menarini Diagnostics has signed a five year distribution agreement with Cambridge Life Sciences Ltd, UK covering Europe for an innovative microarray test system, the Zenit Amidot, together with a range of 5 profiles for the diagnosis of autoimmune diseases. The Zenit Amidot is an OEM co-brand version of CLS's Amidot system.

The microarray, branded will be sold by Menarini as a complementary and integral part of the Autoimmunity portfolio, throughout the whole of Europe and countries of the former Soviet Union such as Russia and Ukraine.

Commenting on the distribution agreement, Crescenzio Izzo, General Manager of A.Menarini Diagnostics, said: "We're very pleased to see that the deal signed between Cambridge Life Sciences and Menarini significantly expands the route to market for Menarini' autoimmune products.The microarray tests developed by Cambridge Life Sciences for autoimmune diseases will enhance our portfolio, offering a new and cost-effective technology."

Peter Blake, CEO of CLS, said: "AMiDot represents a major step forward in the diagnosis and monitoring of Autoimmune Disease and we are pleased to be working with Menarini to commercialise the Zenit AMiDot system throughout Europe. As an independent UK based company Cambridge Life Sciences is committed to the commercialisation of its in house developed technology through appropriate distribution channels whilst at the same time maintaining production capability at its Cambridgeshire headquarters. Menarini are dedicated to Autoimmune Disease Diagnosis, and are a dynamic, forward thinking Marketing and Distribution Company making them the perfect European partner for CLS and AMiDot."




Cambridge Life Sciences is now the exclusive distributor of products from the IMTEC range available from Human GmbH.

For over 35 years HUMAN has been serving the healthcare sector. HUMAN develops and manufactures in Germany laboratory diagnostic products for over 160 countries. An expert team of highly specialized scientists and technicians develop and produce the IMTEC product line, a range of high-quality autoimmune diagnostic products. The extensive autoimmune product line from IMTEC includes ELISA and LIA technologies.

For further information on these products, please contact us





We are now proud to introduce the new specially formulated K8003 Paracetamol 2 Reagent System. The two reagent system avoids the use of multiple pipetting steps and reagent wastage whilst the larger pack size means storage volume is reduced.

click here to read more





Cambridge Life Sciences launches the eagerly awaited AMiDot™ at Medica in Düsseldorf, Germany - an analytical microdot array system for the detection, identification and quantification of autoantibodies in human sera.

click here to read more